Clinical trial
Open Label, Single Arm, Phase II Study Using R-COMP in Elderly Patients With…
NCT00244127 · Zeneus Pharma, Industry · Unknown status
Key facts
| NCT number | NCT00244127 |
|---|---|
| Title | Open Label, Single Arm, Phase II Study Using R-COMP in Elderly Patients With Aggressive NHL. |
| Official title | Cyclophosphamide, Oncovin, Myocet, Prednisone and Rituximab (R-COMP) in the Treatment of Elderly Patients With Aggressive NHL. |
| Lead sponsor | Zeneus Pharma, Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Aggressive Non-Hodgkin's Lymphoma in the Elderly. |
| Intervention type | Drug |
| Interventions | Cyclophosphamide, oncovin, myocet, prednisone & rituximab (R-COMP) |
| Enrollment | 75 |
| Start date | Oct 1, 2002 |
| First posted | Oct 25, 2005 |
| Last update posted | Oct 28, 2005 |
| Countries | France, Germany, Italy, Spain, United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: